en
0.25
0.5
0.75
1.25
1.5
1.75
2
Using human genomic variation for individualisation of drug treatment
Published on 2014-07-211475 Views
There is inherent variation in the responses to drugs used in medicine. This can affect both efficacy and toxicity, which in some individuals leads to a poor benefit-risk ratio of drugs. Strategies
Related categories
Presentation
Using Human Genomic Variation for Individualisation of Drug Treatment00:00
Current Paradigms00:40
“One Dose Fits All” –Variability In Improvement01:35
Adverse Drug Reactions (Side Effects)02:29
A Modern Concept of Personalised Medicine - 103:23
A Modern Concept of Personalised Medicine - 203:57
A Modern Concept of Personalised Medicine - 304:24
A Modern Concept of Personalised Medicine - 404:42
PharmacogenomicVariation in Drug Response05:23
When it works…06:10
Human LeucocyteAntigens (HLA)06:24
Technology-Based Reduction in the Burden of ADRs: The Case of Abacavir Hypersensitivity - 107:54
Technology-Based Reduction in the Burden of ADRs: The Case of Abacavir Hypersensitivity - 208:20
Technology-Based Reduction in the Burden of ADRs: The Case of Abacavir Hypersensitivity - 308:34
Technology-Based Reduction in the Burden of ADRs: The Case of Abacavir Hypersensitivity - 409:22
Effect of Pharmacogenetics on Drug Usage10:00
Change in Peptide Repertoire11:19
HLA-B*57:01 and AbacavirHypersensitivity11:42
When it makes sense…13:12
Genetic Variants in C5 and Poor Response to Eculizumab - 113:22
Genetic Variants in C5 and Poor Response to Eculizumab - 214:29
More often than not, it is difficult…15:14
Sources of Variation15:29
Warfarin - 116:51
Warfarin - 217:30
Variation in Dose Requirements18:23
Determinants of Anticoagulation Control - 119:33
Determinants of Anticoagulation Control - 220:32
GWAS Warfarin Mean Weekly Dose20:55
International Warfarin PharmacogeneticsConsortium (IWPC)22:02
Pharmacogenetic-Based Dosing: Warfarin Randomised Controlled Trial22:38
A RCT of Genotype-Guided Dosing of Warfarin24:26
Differences Between Genotyped-Guided Group and Control Group25:25
A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing26:29
Genomeweb's verdict27:03
How can we explain the differences - 127:48
How can we explain the differences - 228:17
Dosing Algorithms - 128:24
Dosing Algorithms - 229:30
Dosing Algorithm –Day 1 - 130:47
Dosing Algorithm –Day 1 - 231:18
Ethnic Heterogeneity31:55
Control Arms in the Two Trials - 132:56
Control Arms in the Two Trials - 233:58
Efficacy and safety of dabigatran compared with warfrin34:54
Comparison Between COAG and EU-PACT35:29
EU-PACT: Effect of Number of Variants on % Time in Therapeutic Range (TTR)36:21
A RCT of Genotype-Guided Dosing of Acenocomumarol and Phenprocoumon37:53
Differences in Vitamin K antagonists39:01
Pharmacogenetic tests39:53
Drug Exposure: Differential Evidential Standards40:20
Differential Evidence Standards - 141:38
Differential Evidence Standards - 242:22
CYP2C19 genotype-based phase I studies42:57
Response to a drug, efficacy or toxicity, is a complex phenotype44:08
Systems Pharmacology Approaches44:27
Warfarin Dose Prediction45:08
Summary46:04
Future46:41
Acknowledgements47:47